Блог им. gtcapital

SPY с гэпом растет на премаркете

Ближайший уровень поддержки по SPY – 187.00 уровень сопротивления – 188.50

Блог им. gtcapital: SPY с гэпом растет на премаркете

BPL продажа ниже 73,50

PPC смотрим на откат вверх

Gapping up/down: MS and GE +4% after earnings, NVS +2% after NICE draft guidance, AKS and SUNE +6% after upgrades; URBN -13%, SNDK -3% and GOOG -1% after earnings Price: null Change: null

Gapping up
Briefing note: With S&P futures up over 1% in the pre-market, many stocks are gapping higher that are not listed.

In reaction to strong earnings/guidance: QLGC +10.1%, (also Announces Approval of a $100 million Stock Repurchase Program), FHN +6.1%, XLNX +5.7%, CPHD +4.1%, MS +3.8%, GE +3.7%, WDFC +3%, SLB +2.6%, HON +1.9%

M&A news: HZNP +1.9% (announces acquisition of U.S. rights to PENNSAID 2% From Nuvo Research Inc. for $45 mln in cash), EXP +1.8% (to acquire CRS Proppants for ~$225 mln)

Select EU related names showing strength: ING +3.3%, ALU +3%, ASML +2.3%, CS +1.8%

Select Ebola related stocks trading higher: IBIO +11.6%, NLNK +5.1%, LAKE +4.9%

Select oil/gas related names showing strength: PBR +4.1%, STO +3.3%, SDRL +2.9%, HAL +2.2%

Select fan favorites trading higher: GPRO +4.6%, TSLA +2.2%, TWTR +2.1%, AAPL +1.3%

Other news: AMPE +16.3% (announces results of the open label portion of the multiple intra-articular injections study of Ampion), SRPT +9.7% (announces publication of Ebola and Marburg Phase I Clinical Study results in antimicrobial agents and chemotherapy), FMI +9.1% (announced an agreement to enhance precision medicine options for Priority Health members with advanced cancers, also upgraded to Outperform from Mkt Perform at William Blair), BEAT +7.8% (announces reinstatement of Cigna's coverage of Mobile Cardiac Monitoring Services), HCLP +6.1% (announced 9% increase in third quarter 2014 distribution to $0.625 per unit), PPC +2.9% (following weakness in poultry names on SAFM Investor Day comments), NVS +1.9% (NICE has issued final draft guidance proposing to recommend imatinib, also known as Glivec and made by NVS ), X +1.8% (may be in symp with AKS upgrade),.

Analyst comments: AKS +6.1% (upgraded to Buy from Neutral at Nomura), SUNE +5.7% (upgraded to Outperform from Mkt Perform at Cowen), EJ +5.6% (upgraded to Buy from Neutral at Goldman), NBR +2.2% (upgraded to Buy from Neutral at UBS), GS +1.5% (upgraded to Outperform from Mkt Perform at Keefe Bruyette), ISRG +0.9% (upgraded to Outperform at Leerink Partners)

Gapping down
In reaction to disappointing earnings/guidance: URBN -13.6%, (reports Q3 negative comparable retail segment net sale has continued quarter-to-date; gross profit margin may deleverage at a rate greater than during 1H), SNDK -2.8%, ATHN -2%, AMD -1.1%, GOOG -0.9%, COF -0.7%

M&A news: CF -3.9% (announced the termination of merger discussions with Yara International)

Other news: RPRX -40.6% (announces upcoming FDA meeting to be Type C meeting instead of Type B Pre-NDA meeting), CCL -3.4% (Health Care worker who may have handled Thomas Duncan's Ebola lab specimens has been isolated on CCL ship, according to reports), RCL -3% (in symp with CCL news), ANF -1.7% (following URBN guidance), AEO -1.2% (following URBN guidance), EARN -1.1% (co requested the withdrawal of its registration statement on Form S-11; intends to register on Form S-3)

Оригинал статьи: gtstocks.com/analytics-17-10-2014.html

0 комментариев

Оставить комментарий